Lupin launches generic equivalent of Kerydin Topical Solution in US
Mumbai: Global pharma major, Lupin Limited, has announced the US launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (USFDA).
The product will be manufactured at Lupin's facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Tavaborole Topical Solution (RLD: Kerydin), 5% has an estimated annual sales of USD 53 million in the U.S. (IQVIA MAT May 2021).
Read also: Lupin gets CDSCO committee approval for marketing Ranibizumab
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
Read also: Lupin gets USFDA nod to expand Solosec use for Trichomoniasis
